Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

被引：0
|
作者：
Raab, Marc S. [1 ]
Oriol, Albert [2 ]
Sandhu, Irwindeep [3 ]
White, Darrell [4 ,5 ]
Leblanc, Richard [6 ]
Raje, Noopur [7 ]
Ocio, Enrique M. [8 ]
Perrot, Aurore [9 ]
Facon, Thierry [10 ]
Rodriguez, Cesar [11 ]
Waesch, Ralph [12 ]
Amatangelo, Michael [13 ]
Zhou, Zehua [13 ]
Wang, Yue [13 ]
Civardi, Tiziana [14 ]
Koo, Phillip [13 ]
Maciag, Paulo [13 ]
Zhu, Daniell [13 ]
Katz, Jessica [13 ]
Richardson, Paul G. [15 ]
机构：
[1] Univ Klinikum Heidelberg, Heidelberg, Germany
[2] Hosp Badalona Germans Trias & Pujol, Catalan Inst Oncol & Josep Carreras Inst, Badalona, Spain
[3] Univ Alberta, Edmonton, AB, Canada
[4] Dalhousie Univ, Halifax, NS, Canada
[5] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[6] Univ Montreal, Hop Maisonneuve Rosemont, Montreal, PQ, Canada
[7] Massachusetts Gen Hosp, Boston, MA USA
[8] Hosp Univ Marques de Valdecilla IDIVAL, Santander, Spain
[9] Inst Univ Canc Toulouse Oncopole, Toulouse, France
[10] Univ Lille, Ctr Hosp Univ CHU Lille, Serv Malad Sang, Lille, France
[11] Icahn Sch Med Mt Sinai, New York, NY USA
[12] Univ Freiburg, Dept Med, Med Ctr, Freiburg, Germany
[13] Bristol Myers Squibb, Princeton, NJ USA
[14] Celgene Int Sarl, Boudr, Switzerland
[15] Dana Farber Canc Inst, Boston, MA USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335
引用
收藏
页码：115 / 115
页数：1
相关论文
共 50 条
  • [1] Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Philip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S31 - S31
  • [2] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial
    Oriol, Albert
    Sandhu, Irwindeep
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Raje, Noopur
    Ocio, Enrique M.
    Perrot, Aurore
    Facon, Thierry
    Rodriguez, Cesar
    Waesch, Ralph
    Amatangelo, Michael
    Zhou, Zehua
    Wang, Yue
    Civardi, Tiziana
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul G.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S566 - S566
  • [3] Mezigdomide (MEZI; CC-92480) in Combination with Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
    Raab, M. S.
    Richardson, P. G.
    Sandhu, I
    Oriol, A.
    White, D.
    LeBlanc, R.
    Perrot, A.
    Ocio, E. M.
    Raje, N.
    Hansen, C. Toftmann
    Zhou, Z.
    Civardi, T.
    Katz, J.
    Peluso, T.
    Dimopoulos, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 56 - 56
  • [4] Mezigdomide (MEZI; CC-92480) in combination with dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Richardson, Paul
    Sandhu, Irwindeep
    Oriol, Albert
    Raab, Marc S.
    White, Darrell
    LeBlanc, Richard
    Perrot, Aurore
    Ocio, Enrique
    Raje, Noopur
    Hansen, Charlotte Toftmann
    Zhou, Zehua
    Civardi, Tiziana
    Ghiddi, Alessandro
    Katz, Jessica
    Peluso, Teresa
    Dimopoulos, Meletios A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S33 - S33
  • [5] Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Daratumumab (DARA) or Elotuzumab (ELO) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the CC-92480-MM-002 Trial
    Richardson, Paul G.
    Sandhu, Irwindeep
    Hofmeister, Craig C.
    Orlowski, Robert Z.
    White, Darrell
    Belotti, Angelo
    Hansen, Charlotte Toftmann
    Raje, Noopur S.
    Chow, Tracy T.
    Zhou, Zehua
    Civardi, Tiziana
    Koo, Phillip
    Zhu, Yue
    Katz, Jessica
    Oriol, Albert
    BLOOD, 2023, 142
  • [6] Initial results of phase 1/2 study CC-92480-MM-002 onCELMoD CC-92480 in combination with bortezomib (BORT)and dexamethasone (DEX) in patients with relapsed /refractory multiple myeloma (RRMM)
    Raab, M. -S.
    Richardson, P. G.
    Ocio, E. M.
    Raje, N.
    Gregory, T.
    White, D.
    Oriol, A.
    Sandhu, I.
    LeBlanc, R.
    Rodriguez Valdes, C.
    Trudel, S.
    Waesch, R.
    Perrot, A.
    Bahlis, N. J.
    Zhou, Z.
    Lamba, M.
    Amatangelo, M.
    Civardi, T.
    Katz, J.
    Maciag, P.
    Peluso, T.
    Dimopoulos, M. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 86 - 86
  • [7] Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial
    Orlowski, Robert Z.
    Bahlis, Nizar J.
    Quach, Hang
    Popat, Rakesh
    Lonial, Sagar
    Kim, Kihyun
    Mateos, Maria-Victoria
    Pawlyn, Charlotte
    Ramasamy, Karthik
    Martinez-Lopez, Joaquin
    Casas-Aviles, Ignacio
    Spirli, Alessia
    Gong, Jing
    Amatangelo, Michael
    Katz, Jessica
    Maciag, Paulo
    Peluso, Teresa
    Richardson, Paul G.
    Trudel, Suzanne
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S492 - S493
  • [8] Mezigdomide (MEZI) monotherapy in relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-001 trial
    Goldsmith, Scott
    Oriol, Albert
    Anttila, Pekka
    Bahlis, Nizar
    Berdeja, Jesus
    Cowan, Andrew
    Dimopoulos, Meletios
    Foster, Laahn
    Hillengass, Jens
    Louzada, Martha
    Wu, Ka Lung
    Chow, Tracy
    Chen, Wencong
    Wang, Yue
    Spirli, Alessia
    Koo, Phillip
    Maciag, Paulo
    Zhu, Daniel
    Katz, Jessica
    Richardson, Paul
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S181 - S182
  • [9] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Lonial, Sagar
    Richardson, Paul G.
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, A.
    Knop, Stefan
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David S.
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    van de Donk, Niels W. C. J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S9 - S9
  • [10] Iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
    Knop, Stefan
    Lonial, Sagar
    Richardson, Paul
    Popat, Rakesh
    Stadtmauer, Edward A.
    Larsen, Jeremy T.
    Oriol, Albert
    Jagannath, Sundar
    Cook, Gordon
    Badros, Ashraf Z.
    Rodriguez-Otero, Paula
    Siegel, David
    Nguyen, Tuong Vi
    Di Micco, Antonia
    Amin, Alpesh
    Chen, Min
    Kueenburg, Elisabeth
    Van De Donk, Niels W. C. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 171 - 171
12345